
H. B. 4666
(By Delegates Warner, Leach, Boggs, Campbell,
Proudfoot and Fletcher)
(Originating in the Committee on Finance)
[February 27, 2002]
A BILL to amend and reenact section fifteen, article five, chapter
nine of the code of West Virginia, one thousand nine hundred
thirty-one, as amended, relating to establishing a process for
the secretary of health and human services to enter into
negotiations with pharmaceutical companies for rebates that
cannot be accessed through Freedom of Information Act requests
or through open meetings.
Be it enacted by the Legislature of West Virginia:
That section fifteen, article five, chapter nine of the code
of West Virginia, one thousand nine hundred thirty-one, as amended,
be amended and reenacted to read as follows:
ARTICLE 5. MISCELLANEOUS PROVISIONS.
§9-5-15. Medicaid program; preferred drug list and drug
utilization review
.

The drug formulary committee of the department of human
services shall meet no less than four times each year and be
responsible for the development of a drug formulary which shall consist of cost effective federal food and drug administration
approved generic drugs, when applicable. Medicaid shall pay for
only these generic products, when applicable, in accordance with
federal medicaid regulations and guidelines.

The Legislature finds that it is a public necessity that trade
secrets, rebate amounts, percentage of rebate, manufacturer's
pricing and supplemental rebates that are contained in records, as
well as any meetings at which this information is negotiated or
discussed need confidentiality to insure the most significant
rebates available for the state. Information pertaining to similar
agreements with the federal government and negotiated by
pharmaceutical manufacturers is confidential pursuant to 42 U.S.C
1396r-8. A rebate as a percentage of average manufacture price is
confidential under federal law and the federal rebate could be made
known if not protected by state law. Because of the protection
afforded by federal law, if this information is not protected by
state law, manufacturers will not be willing to offer a rebate in
West Virginia. Further, the Legislature finds that the number and
value of supplemental rebates obtained by the department will
increase, to the benefit of Medicaid recipients, if information
related to the supplemental rebates is protected in the records of
the department and in meetings in which this information is
disclosed because manufactures will be assured they will not to be
placed at a competitive disadvantage by exposure of this
information.
The secretary of the department of health and human resources has the authority to develop a preferred drug list, in accordance
with federal law, which shall consist of federally approved drugs.
The department, through administration of the medicaid program, may
reimburse, where applicable and in accordance with federal law,
entities providing and dispensing prescription drugs from the
preferred drug list.
The secretary of the department is hereby authorized to
negotiate and enter into agreements with pharmaceutical
manufacturers for supplemental rebates for medicaid reimbursable
drugs.
The provisions of article three, chapter five-a of this code
shall not apply to any contract or contracts entered into under
this section.
Trade secrets, rebate amounts, percentage of rebate,
manufacturer's pricing and supplemental rebates which are contained
in the department's records and those of its agents with respect to
supplemental rebate negotiations and which are prepared pursuant to
a supplemental rebate agreement are confidential and exempt from
all of article one, chapter twenty-nine-b of this code.
Those portions of any meetings of the committee at which trade
secrets, rebate amounts, percentage of rebate, manufacturer's
pricing and supplemental rebates are disclosed for discussion or
negotiation of a supplemental rebate agreement are exempt from all
of article nine-a, chapter six of this code.
The secretary of the department will monitor and evaluate the
effects of this provision on medicaid recipients, the medicaid program, physicians and pharmacies.
The commissioner shall implement a drug utilization review
program to assure that prescribing and dispensing of drug products
result in the most rational cost-effective medication therapy for
medicaid patients.
Any moneys received in supplemental rebates will be deposited
in the medical services fund established in section two, article
four, chapter nine of this code.